Skip to main content
. 2021 Nov 24;6(6):100319. doi: 10.1016/j.esmoop.2021.100319

Figure 2.

Figure 2

Frequency of MET dependency in lung cancer.

The inner ring represents known primary oncogenic driver alterations in metastatic lung cancers, such as EGFR, ALK, RET, KRAS, and BRAF. The outer ring illustrates known resistance mechanisms in these oncogenic-driven NSCLC subsets: frequency of MET amplification (red) is ∼15% in EGFR, KRAS, and ALK- and RET-fusion-positive NSCLC. Taken together, these data highlight that ∼7%-10% of NSCLC tumors are MET dependent, including de novo METex14 and high MET amplification. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer.